CA2616721C - Methods for treating substance-related disorders - Google Patents

Methods for treating substance-related disorders Download PDF

Info

Publication number
CA2616721C
CA2616721C CA2616721A CA2616721A CA2616721C CA 2616721 C CA2616721 C CA 2616721C CA 2616721 A CA2616721 A CA 2616721A CA 2616721 A CA2616721 A CA 2616721A CA 2616721 C CA2616721 C CA 2616721C
Authority
CA
Canada
Prior art keywords
withdrawal
substance
formula
enantiomer
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2616721A
Other languages
English (en)
French (fr)
Other versions
CA2616721A1 (en
Inventor
Carlos R. Plata-Salaman
Boyu Zhao
Roy E. Twyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of CA2616721A1 publication Critical patent/CA2616721A1/en
Application granted granted Critical
Publication of CA2616721C publication Critical patent/CA2616721C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2616721A 2005-07-26 2005-07-26 Methods for treating substance-related disorders Expired - Lifetime CA2616721C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/026439 WO2007018496A1 (en) 2005-07-26 2005-07-26 Methods for treating substance-related disorders

Publications (2)

Publication Number Publication Date
CA2616721A1 CA2616721A1 (en) 2007-02-15
CA2616721C true CA2616721C (en) 2014-01-21

Family

ID=35064669

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2616721A Expired - Lifetime CA2616721C (en) 2005-07-26 2005-07-26 Methods for treating substance-related disorders

Country Status (13)

Country Link
EP (1) EP1928451B1 (enExample)
JP (1) JP5094720B2 (enExample)
KR (1) KR101199499B1 (enExample)
CN (1) CN101272776B (enExample)
AT (1) ATE538784T1 (enExample)
AU (1) AU2005335241B9 (enExample)
BR (1) BRPI0520451A2 (enExample)
CA (1) CA2616721C (enExample)
EA (1) EA019935B1 (enExample)
ES (1) ES2385087T3 (enExample)
IL (1) IL189003A0 (enExample)
NO (1) NO20080877L (enExample)
WO (1) WO2007018496A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
RU2557533C2 (ru) 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
BR112015022197B1 (pt) 2013-03-13 2022-06-07 Sk Biopharmaceuticals Co., Ltd. Uso de um composto para o tratamento de cataplexia
CN105873576B (zh) 2013-07-18 2019-07-19 爵士制药国际Iii有限公司 治疗肥胖
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR20240162165A (ko) 2017-06-02 2024-11-14 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
JP7257091B2 (ja) * 2019-06-27 2023-04-13 沼澤 敏彦 認知症の治療及び予防薬
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
KR100886578B1 (ko) * 2001-02-27 2009-03-05 오르토-맥네일 파마슈티칼, 인코퍼레이티드 카바메이트 화합물을 포함하는 정신증 장애 예방용 또는 치료용 약제학적 조성물
BR0207832A (pt) * 2001-02-27 2004-06-22 Ortho Mcneil Pharm Inc Compostos de carbamato para uso na prevenção ou tratamento de distúrbio bipolar
ATE369130T1 (de) * 2001-02-27 2007-08-15 Ortho Mcneil Pharm Inc Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
PT1383489E (pt) * 2001-02-27 2007-06-21 Ortho Mcneil Pharm Inc Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Also Published As

Publication number Publication date
AU2005335241A1 (en) 2007-02-15
ATE538784T1 (de) 2012-01-15
EP1928451A1 (en) 2008-06-11
CN101272776B (zh) 2012-10-03
AU2005335241B2 (en) 2012-11-15
JP2009502914A (ja) 2009-01-29
IL189003A0 (en) 2008-11-03
NO20080877L (no) 2008-02-19
BRPI0520451A2 (pt) 2009-05-12
EP1928451B1 (en) 2011-12-28
EA019935B1 (ru) 2014-07-30
KR20080037055A (ko) 2008-04-29
ES2385087T3 (es) 2012-07-18
WO2007018496A1 (en) 2007-02-15
JP5094720B2 (ja) 2012-12-12
EA200800422A1 (ru) 2008-10-30
KR101199499B1 (ko) 2012-11-09
AU2005335241B9 (en) 2012-12-20
CA2616721A1 (en) 2007-02-15
CN101272776A (zh) 2008-09-24

Similar Documents

Publication Publication Date Title
CA2764665C (en) Compositions for treating drug addiction and improving addiction-related behavior
JP5901528B2 (ja) 線維筋痛症候群の治療方法
CA2616721C (en) Methods for treating substance-related disorders
KR100858232B1 (ko) 카바메이트 화합물을 포함하는 거동 장애 예방 또는 치료용 약제학적 조성물
CA2439480C (en) Carbamate compounds for use in preventing or treating psychotic disorders
NZ565188A (en) The use of carbamate derivatives to treat drug withdrawal disorders
EP1408954B1 (en) Carbamate compounds for use in preventing or treating neuropathic pain
US20070129445A1 (en) Therapeutic Agents
AU2002322442B2 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
HK1209058B (en) Compositions for treating drug addiction and improving addiction-related behavior
HK1176285B (en) Compositions for treating drug addiction and improving addiction-related behavior

Legal Events

Date Code Title Description
EEER Examination request